Currently, ERBB-targeted therapeutics in clinical use includes trastuzumab for metastatic breast cancer overexpressing ERBB2, cetuximab for colorectal cancer, gefetinib and erlotinib as a second-line treatment for non-small cell lung cancer (Hynes and Lane, 2005; Johnston et al, 2006). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.